ENGN - Latest News
enGene Holdings Inc. (ENGN), operates in Healthcare / Biotechnology, trades on NASDAQ.
Market capitalization stands near $113.9M. Beta to the broader market is -0.28.
The article list below shows the most recent ENGN headlines from major financial news vendors. For options traders, the most actionable items are earnings releases, analyst rating changes, M&A activity, and regulatory filings - each can drive a meaningful repricing of implied volatility and shift dealer hedging flow. Pair the news context with the implied-volatility skew and gamma exposure views to see whether the options market has already priced in the headline.
Recent ENGN Headlines
Contrasting Oncobiologics (NASDAQ:OTLK) & enGene (NASDAQ:ENGN)
defenseworld.net - Aug 15, 2026
enGene (NASDAQ: ENGN - Get Free Report) and Oncobiologics (NASDAQ: OTLK - Get Free Report) are both small-cap healthcare companies, but which is the s
enGene Eyes 2027 Approval as Detalimogene Targets Expanding Bladder Cancer Market
marketbeat.com - Aug 13, 2026
enGene NASDAQ: ENGN outlined its view of the high-risk Bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer, or NMIBC, market, cit
enGene Therapeutics Inc. (ENGN) Discusses Market Insights and Clinical Development in Non-Muscle Invasive Bladder Cancer Transcript
seekingalpha.com - Aug 11, 2026
enGene Therapeutics Inc.
enGene to Host Virtual KOL Event to Discuss Emerging Non-Muscle Invasive Bladder Cancer (NMIBC) Market Insights, on August 11, 2026
businesswire.com - Aug 4, 2026
BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Therapeutics Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines
enGene Focuses Board to Support Planned Upcoming Regulatory and Commercial Milestones
businesswire.com - Jul 16, 2026
BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Therapeutics Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines
How News Affects ENGN Options Pricing
Headlines and scheduled events drive implied volatility in two distinct ways. Pre-event, IV typically inflates as uncertainty about the outcome rises; this is the implied-volatility expansion that creates the long-vol setup. Post-event, IV typically contracts sharply as uncertainty resolves; this is IV crush, which makes premium-selling structures profitable when they survive the underlying move. The size of the crush depends on how stretched pre-event IV is relative to the realized move. Track ENGN's implied vs realized volatility over the news cycle to size pre-event vs post-event positioning. For ticker-level dealer positioning context, the gamma exposure view shows whether dealers are positioned to amplify or dampen post-news moves.
Frequently asked ENGN news questions
- What is the latest ENGN news headline?
- The most recent ENGN headline (Aug 15, 2026) is "Contrasting Oncobiologics (NASDAQ:OTLK) & enGene (NASDAQ:ENGN)". The five most recent stories with summaries and publication times are listed above, sourced from major financial news vendors.
- How fresh is the ENGN news on this page?
- News rows refresh roughly every 30 minutes during the trading day. The five most recent headlines are listed in publication-time order. Press releases from the company itself typically appear within minutes of the wire release; third-party reporting may lag by 30-60 minutes depending on the source.
- What ENGN news moves options pricing?
- Three categories move single-name IV most aggressively: scheduled earnings releases (priced into pre-event IV, crushed post-event), unscheduled M&A or strategic announcements (rapid IV expansion, slower decay), and regulatory or legal events (drug-trial readouts, antitrust filings, FDA approvals). Routine news flow (analyst commentary, sector rotation) typically does not move IV meaningfully unless it triggers a cluster of rating changes.
- How can I track unusual ENGN options activity related to news?
- Unusual options activity often precedes news by hours to days; the canonical signals are volume substantially above the trailing average concentrated in a small number of strikes, atypical put/call skew, and aggressive execution (at-the-ask sweeps or block prints). Cross-reference the per-ticker gamma-exposure and volume-history pages with the news flow above to triangulate informed vs uninformed flow.